Development and Evaluation of Prognostic Nomogram Model for Adult Ventricle Glioma Patients
Abstract
To explore the prognostic factors of adult ventricle glioma (AVG) and to construct and evaluate a survival-related prognostic nomogram model, which could provide further reference for the clinical management of AVG patients. Methods The patients covered in the study were selected from the Surveillance Epidemiology and End Results (SEER) database (1973–2016). They all had definite histological diagnosis of AVG. They were assigned randomly to the training cohort and the validation cohort by random number table at a 2/1 ratio. Survival analysis was performed by Kaplan-Meier analysis. Cox regression analysis was employed to determine the independent prognostic factors for overall survival (OS) and cancer-specific survival (CSS). Then, integrating the basic characteristics of patients, the survival-related nomogram predictive model for OS and CSS in the training cohort was constructed, respectively. After that, internal cross validation and external validation of the model were carried out with the training cohort and the validation cohort in succession. The authenticity and reliability of the nomogram model were evaluated by calculating the concordance index (C-index). Calibration plots were constructed to assess the agreement between the predicted values and the observed values in the training cohort and the validation cohort. Results A total of 369 AVG patients, including 218 males and 151 females, were included. The median age of the patients was 53. According to the WHO classification of gliomas, 66 (17.9%) patients had grade Ⅱ gliomas, 73 (19.8%) had grade Ⅲ gliomas, and 230 (62.3%) had grade Ⅳ gliomas. Regarding the extent of resection (EOR), 59 (16.0%) had gross total resection (GTR) and 145 (39.3%) had subtotal resection (STR) or partial resection (PR). Of all the patients, 167 (45.3%) received postoperative radiotherapy and 143 (38.8%) received postoperative chemotherapy. Patients were randomized into the training cohort (n=246) and the validation cohort (n=123), and there was no significant difference (P>0.05) in the basic clinical characteristics between the training cohort and the validation cohort. In the training cohort, Cox regression analysis revealed that the independent prognostic factors for OS and CSS included age≥65, grades Ⅲ and Ⅳ according to the WHO classification of gliomas, and not receiving radiotherapy. Furthermore, 5 variables, including age, gender, WHO grades, surgery, and radiotherapy, were used to construct the nomogram model for predicting 6-month, 1-year, and 2-year OS and CSS. The results of internal cross validation in the training cohort showed that the C-indexes of OS and CSS were 0.758 and 0.765, respectively. The external validation results of the validation cohort showed that the C-indexes of OS and CSS were 0.733 and 0.719, respectively. Calibration plots for 6-month, 1-year, and 2-year OS in the training cohort showed relatively good agreement, while in the validation cohort the agreement was relatively low. The 6-month, 1-year, and 2-year CSS calibration plots had results similar to the calibration plots of OS. Conclusion This nomogram predictive model of OS and CSS showed moderately reliable predictive performance, providing helpful reference information for clinicians to make quick and simple assessment of the survival probability of AVG patients.
Keywords: Ventricleglioma, Nomogram, Prognostic model, SEER, Overall survival, Cancer-specific survival.
Full Text:
PDFReferences
OSTROM Q T， CIOFFI G， GITTLEMAN H， et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol，2019，21: V1–V100.
LOUIS D N， PERRY A， REIFENBERGER G， et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol，2016，131(6): 803–820.
NITTA N， MORITANI S， FUKAMI T， et al. Intraventricular epithelioid glioblastoma: A case report. World Neurosurg，2018，112: 257–263.
BEN NSIR A， GDOURA Y， THAI Q A， et al. Intraventricular glioblastomas. World Neurosurg，2016，88: 126–131.
ZHANG J， SHRESTHA R， LI J， et al. Fourth ventricle glioblastoma. Clin Neurol Neurosurg，2012，114(8): 1164–1167.
PRIETO R， PASCUAL J M， RODA J M. Third ventricle glioblastoma. Case report and review of literature. Clin Neurol Neurosurg，2006，108(2): 199–204.
GOLLAPALLI K， GHANTASALA S， KUMAR S， et al. Subventricular zone involvement in glioblastoma--A proteomic evaluation and clinicoradiological correlation. Sci Rep，2017，7(1): 1449.
VERGANI F， MARTINO J， GOZÉ C， et al. World health organization grade Ⅱ gliomas and subventricular zone: Anatomic, genetic, and clinical considerations. Neurosurgery，2011，68(5): 1293–1298.
VAN DIJKEN B R J， VAN LAAR P J， LI C， et al. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma. J Neurosurg，2019，131(3): 717–723.
CIKLA U， SWANSON K I， TUMTURK A， et al. Microsurgical resection of tumors of the lateral and third ventricles: Operative corridors for difficult-to-reach lesions. J Neuro Oncol，2016，130(2): 331–340.
MISTRY A M， MUMMAREDDY N， CREVECOEUR T S， et al. Association between supratentorial pediatric high-grade gliomas involved with the subventricular zone and decreased survival: A multi-institutional retrospective study. J Neurosurg，2020，26(3): 288–294.
COONEY T， LANE A， BARTELS U， et al. Contemporary survival endpoints: An international diffuse intrinsic pontine glioma registry study. Neuro Oncol，2017，19(9): 1279–1280.
PICART T， BARRITAULT M， BERTHILLIER J， et al. Characteristics of cerebellar glioblastomas in adults. J Neurooncol，2018，136(3): 555–563.
SECER H I， DINC C， ANIK I， et al. Glioblastoma multiforme of the lateral ventricle: Report of nine cases. Br J Neurosurg，2008，22(3): 398–401.
SARSILMAZ A， GELAL F， APAYDIN M， et al. Intraventricular glioblastoma multiforme a pediatric case report. J Pediatr Hematol Oncol，2010，32(6): 519–522.
PIEPMEIER J M. Tumors and approaches to the lateral ventricles: Introduction and overview. J Neurooncol，1996，30(3): 267–274.
NIU X， WANG T， ZHOU X， et al. Surgical treatment and survival outcome of patients with adult thalamic glioma: A single institution experience of 8 years. J Neurooncol，2020，147(2): 377–386.
STUPP R， BRADA M， VAN DEN BENT M J， et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol，2014，25: 93–101.
OLAR A， WANI K M， ALFARO-MUNOZ K D， et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade Ⅱ–Ⅲ diffuse gliomas. Acta Neuropathol，2015，129(4): 585–596.
TABOURET E， NGUYEN A T， DEHAIS C， et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol，2016，132(4): 625–634.
CHIANG G C， GALLA N， FERRARO R， et al. The added prognostic value of metabolic tumor size on FDG-PET at first suspected recurrence of glioblastoma multiforme. J Neuroimaging，2017，27(2): 243–247.
BROWN T J， BRENNAN M C， LI M， et al. Association of the extent of resection with survival in glioblastoma. JAMA Oncol，2016，2(11): 1460.
PATEL T， BANDER E D， VENN R A， et al. The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas. Neurosurgery， 2018，82(6): 808–814.
MARTINEZ-VELEZ N， MARIGIL M， GARCÍA-MOURE M， et al. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathol Commun，2019，7(1): 64.
BELL E H， ZHANG P， FISHER B J， et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: An analysis from the NRG Oncology/RTOG 0424 Trial. JAMA Oncol，2018， 4(10): 1405–1409.
STUPP R， MASON W P， VAN DEN BENT M J， et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med，2005，352(10): 987–996.
Refbacks
- There are currently no refbacks.
